Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
MapLight goes public via $250M IPO to fund Cobenfy competitor
MapLight is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its challenger to BMS’ Cobenfy.
James Waldron
Oct 27, 2025 6:45am
Boehringer, Click DTx hits phase 3 goal in schizophrenia
Oct 14, 2025 12:08pm
MapLight illuminates $262M IPO plans to fund Cobenfy competitor
Oct 7, 2025 6:30am
Big Pharma-backed MapLight plots IPO
Sep 22, 2025 1:57pm
CNS biotech attempts to break the IPO ice
Aug 25, 2025 11:10am
Atai's schizophrenia drug fails to improve cognition in phase 2
Jul 28, 2025 7:45am
